Lamellar Ichthyosis Market

DelveInsight’s ‘Lamellar Ichthyosis (LI)-Market Insights, Epidemiology and Market Forecast-2030’ report delivers an in-depth understanding of the Lamellar Ichthyosis, historical and forecasted epidemiology as well as the Lamellar Ichthyosis market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) and Japan.

The Lamellar Ichthyosis market report provides current treatment practices, emerging drugs, Lamellar Ichthyosis market share of the individual therapies, current and forecasted Lamellar Ichthyosis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Lamellar Ichthyosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2017–2030

Lamellar Ichthyosis (LI): Disease Understanding and Treatment Algorithm

Lamellar Ichthyosis Overview

Ichthyosis is the term used to define repetitive and widespread scaling of the skin. It may be inherited (genetic) or acquired during the lifespan. The inherited forms are rare, usually present from infancy, and generally lifelong situations. Acquired Ichthyosis can progress at any age due to several medical problems, such as kidney disease. The most common forms of inherited Ichthyosis are mild, and it might improve during warm climate. There are many very rare conditions where Ichthyosis occurs with problems in other systems of the body.


Inherited Ichthyosis is due to a single genetic trait that is passed on either from one or both parents or develops as a new error in the gene very early in fetal life. It can be mild as with Ichthyosis Vulgaris, or severe.


Lamellar Ichthyosis is a rare genetic disorder, where skin cells are produced at a normal rate, but they do not separate normally at the surface of the outermost layer of skin and are not shed as quickly as they should be which lead to the formation of scale.


The signs and symptoms of Lamellar Ichthyosis differ from individual to individual. Some have mild signs and symptoms, while for others it might be severe.


Lamellar Ichthyosis Diagnosis

It is mainly caused by the mutations affecting several different genes, the genes which mainly involved in Lamellar Ichthyosis include TGM1, ABCA12, CYP4F22, NIPAL4 and others like LIPN, ALOX12B. However, most of the cases (~90%) are caused due to mutation in the TGM1 gene.


Mutations in lamellar Ichthyosis commonly transmitted through autosomal recessive inheritance. Individuals must inherit two recessive genes for lamellar Ichthyosis to show the disease, one from each parent. Also, the diagnosis of a genetic or rare disease can often be puzzling. Healthcare specialists usually look at an individuals’ medical history, symptoms, physical exam, and laboratory test results to make a diagnosis. The patient’s history includes thorough family history.


The diagnosis of Lamellar Ichthyosis is mainly done skin biopsy for histological analysis, electron microscopy, DNA sequencing analysis and immunohistochemical analysis and Ultrasonography.


Lamellar Ichthyosis Treatment

Currently, there is no approved therapy for the treatment of Lamellar Ichthyosis, however, the off-label therapies like retinoids, emollients, and keratolytics are available for symptomatic treatment like removal of scales.


The general treatment course is aimed at controlling symptoms with exfoliating creams and ointments application being found to be crucial. Prescription creams and ointments containing alpha hydroxy acids, such as lactic acid and glycolic acid, help control scaling and increase skin moisture. Keratolytic agents such as 1-5% salicylic acid may be added to emollient cream bases to encourage exfoliation of scale, but are often too irritant for regular use.

Lamellar Ichthyosis Epidemiology

The Lamellar Ichthyosis epidemiology division provide the insights about historical and current Lamellar Ichthyosis patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


Key Findings

  • The total prevalent cases of Lamellar Ichthyosis in the 7MM were found to be 4,038 in 2017 which is expected grow during the study period, i.e., 2017–2030.
  • The disease epidemiology covered in the report provides historical as well as forecasted Lamellar Ichthyosis epidemiology [segmented as Total Prevalent Cases of Lamellar Ichthyosis, Total Diagnosed Cases of Lamellar Ichthyosis, Genetic Mutation-specific Cases of Lamellar Ichthyosis, Severity-Specific Cases of Lamellar Ichthyosis, and Total Treated Cases of Lamellar Ichthyosis] scenario of Lamellar Ichthyosis in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.


Country Wise- Lamellar Ichthyosis Epidemiology

Estimates show the highest prevalent population of Lamellar Ichthyosis is in the United States followed by Japan, Germany, France, and the United Kingdom in the year 2017.

Lamellar Ichthyosis Drug Chapters

Drug chapter segment of the Lamellar Ichthyosis report encloses the detailed analysis of Lamellar Ichthyosis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Lamellar Ichthyosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


Lamellar Ichthyosis Emerging Drugs


TMB-001 (Isotretinoin, formerly known as PAT-001): Timber Pharmaceuticals

TMB-001 (topical isotretinoin) is under clinical development for the treatment of moderate to severe subtypes of congenital ichthyosis. It is a topical ointment formulation (0.05% and 0.1%) of isotretinoin, utilizing Timber's proprietary IPEG delivery system.

In April 2014, the US FDA granted an orphan drug designation to TMB 001 for the treatment of Congenital Ichthyosis. Also in February 2019, Timber Pharmaceuticals, and Patagonia Pharmaceuticals entered into the “Asset Acquisition Agreement”, under which Timber Pharmaceuticals purchased the topical formulation of isotretinoin for the treatment of Congenital Ichthyosis and identified as PAT-001.

Product detailed in Report...


Trifarotene (CD5789): Galderma/Mayne Pharma

Trifarotene is a new chemical entity, currently being investigated by Galderma and Mayne Pharma for autosomal recessive ichthyosis with lamellar scale. It is a novel retinoid in a topical cream formulation with high selectivity for the type of Retinoic Acid Receptor (RAR) found specifically on the skin. As per the company, the drug absorb quickly and might have a low potential for toxicity than retinoid given orally or other existing topical retinoid.


In July 2014, the US FDA granted orphan drug designation to Trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma planned to implement a clinical development plan, reinforcing its commitment to exploring new treatment options for rare diseases, as well as meeting the needs of all patients with skin diseases over the course of their lives.


Also, in June 2017, Mayne Pharma entered into a global licensing agreement with Nestlé Skin Health (parent entity of leading global dermatology and skin health franchise, Galderma) to develop and commercialize a new chemical entity, Trifarotene, in rare disease indications.

Product detailed in Report...


KB105: Krystal Biotech

Krystal Biotech is investigating KB105, which is an HSV-1 based gene therapy engineered to deliver a human transglutaminase-1 (TGM1) gene to patients with TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI).


KB105 works by entering permeabilized skin and by transducing keratinocytes (native TGM1- producing cells). After that, it gets transported episomally, into the nucleus of transduced cells and the vector genome is deposited. Now, TGM1 transcripts are generated, which allows the cell to produce functional TGM1 protein that localizes to the cell membrane. TGM1 crosslinks target proteins to aid in the formation of the cornified cell envelope. This layer formed is known as the Stratum Corneum which acts as a mechanical barrier to protect against transepidermal water loss (TEWL) and entry of infectious agents. It is important to mention that, in vitro and in vivo proof-of-concept and safety had established that KB105 efficiently transduces patient keratinocytes to express functional human TGM1.


In October 2019, the US FDA granted Fast Track designation to KB105 in patients with TGM1 deficient ARCI. Additionally, in the same month, the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) also granted orphan drug designation to KB105.

Before this, in August 2018, the US FDA had also granted a rare Pediatric Disease Designation to KB105 for the treatment of patients with TGM-1-deficient Autosomal Recessive Congenital Ichthyosis (HCPLive, 2018).

Product detailed in Report...

Lamellar Ichthyosis Market Outlook

As of now, there is no therapy approved by the regulatory authorities for the treatment of this rare condition. The treatment of Lamellar Ichthyosis comprises of mainly oral retinoids and a wide variety of creams containing hydrating and keratolytic agents such as urea, propylene glycol, salicylic acid, and alpha-hydroxy acids.


Topical or oral retinoids are mainly used in the severe forms of Lamellar Ichthyosis but the use of retinoids is limited due to their side effects and expense. The commonly used retinoids are isotretinoin and acitretin. Although these agents are very effective in removing scale but they can cause side effects like elevated blood fats, and calcification of tendons and ligaments. The decision to treat with systemic retinoids requires consultation with a physician experienced in their use for ichthyosis.


Furthermore, commonly used keratolytics include salicylic acid, urea, and alpha-hydroxy acids such as lactic and glycolic acids; these are contained in many over the counter and prescription lotions, creams, and ointments. However, some keratolytics such as salicylic acid can be absorbed through the skin with potentially harmful side effects on the body. Side effect, in addition to some concerns about potential toxicity, limits their usefulness in infants and pre-school children.


Key Findings

According to DelveInsight, Lamellar Ichthyosis market in the 7MM is expected to change in the study period 2017–2030. The therapeutic market of Lamellar Ichthyosis in seven major markets was found to be USD 3.9 million in 2017 which is expected to increase during the study period (2017–2030).


The United States Market Outlook

In 2017, the total market size of Lamellar Ichthyosis therapies was estimated to be USD 1.9 million in the United States which is expected to increase in the study period (2017–2030).


EU-5 Countries: Market Outlook

In 2017, the total market size of Lamellar Ichthyosis therapies was found to be USD 1.4 million in the EU-5 countries which is expected to increase in the study period (2017–2030).


Japan Market Outlook

The total market size of Lamellar Ichthyosis therapies in Japan was found to be USD 0.5 million in 2017 which is also expected to increase during the study period (2017–2030).

Lamellar Ichthyosis Pipeline Development Activities

The drugs which are in pipeline includes:

1. TMB-001 (Isotretinoin) (Timber Pharmaceuticals): Phase II

2. Trifarotene (CD5789) (Galderma/Mayne Pharma): Phase II

3. KB105 (Krystal Biotech): Phase I/II


Pipeline Development Activities

Key Points

  • In September 2018, the US FDA awarded USD 1.5 million to support phase IIa and Phase IIb clinical trials evaluating TMB-001 through its Orphan Products Grant program.
  • Timber initiated a Phase IIb randomized, parallel, double-blind, vehicle-controlled study in December 2019. The purpose of this study is to investigate the efficacy and safety of two concentrations of topically applied TMB-001 in subjects nine years of age and older. In order to generate high quality data that will allow the appropriate Phase III dose selection in the ongoing Phase IIb dose ranging study, Timber is working with leading experts in the field.
  • In June 2019, Krystal Biotech submitted an IND application with the US FDA to initiate a Phase I/II of KB105.

Lamellar Ichthyosis Drugs Uptake

Due to in vitro and in vivo proof-of-concept and safety which showed that KB105 (gene therapy) efficiently transduces patient keratinocytes to express functional human TGM1 and designations like fast track, rare pediatric disease and orphan designation KB105 is expected to impact the therapeutic market of Lamellar Ichthyosis significantly also Trifarotene (CD5789 Cream) owing to more specific mechanism as claimed by company, is expected to have significant impact on the market


Access and Reimbursement Scenario in Lamellar Ichthyosis Therapies

• The access and reimbursement of the therapies for Lamellar Ichthyosis are difficult as current agents are associated with side effects and cost-effectiveness is also a major concern. Additionally, these agents are not approved by the US FDA which is making their access and reimbursement even more difficult.

• Other barriers like conducting the clinical trials that would be needed to support US FDA approval of retinoids for ichthyoses. Because of these barriers, the present therapies are usually not reimbursed by insurance carriers and therapies can result in significant out-of-pocket expenses for families.

KOL- Views

To keep up with current market trends, we take KOL’s and SME’s opinion working in Lamellar Ichthyosis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Lamellar Ichthyosis market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Lamellar Ichthyosis Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Lamellar Ichthyosis, explaining its causes, signs and symptoms, pathophysiology and currently available therapies

• Comprehensive insight has been provided into the Lamellar Ichthyosis epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Lamellar Ichthyosis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of Lamellar Ichthyosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Lamellar Ichthyosis market

Report Highlights

• In the coming years, Lamellar Ichthyosis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the Size of the market to enable the drug manufacturers to penetrate more into the market

• The companies and academics are working to assess challenges and seek opportunities that could influence Lamellar Ichthyosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition

• Major players are involved in developing therapies for Lamellar Ichthyosis. Launch of emerging therapies, will significantly impact the Lamellar Ichthyosis market

• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Lamellar Ichthyosis.

• Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase I/II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Lamellar Ichthyosis Report Insights

• Patient Population

• Therapeutic Approaches

• Lamellar Ichthyosis Pipeline Analysis

• Lamellar Ichthyosis Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Lamellar Ichthyosis Report Key Strengths

• 11 Years Forecast

• 7MM Coverage

• Lamellar Ichthyosis Epidemiology Segmentation

• Key Cross Competition

• Highly Analyzed Market

• Drugs Uptake

Lamellar Ichthyosis Report Assessment

• Current Treatment Practices

• Unmet Needs

• Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Lamellar Ichthyosis Market share (%) distribution in 2017 and how it would look like in 2030?

• What would be the Lamellar Ichthyosis total market Size as well as market Size by therapies across the 7MM during the study period (2017–2030)?

• What are the key findings pertaining to the market across the 7MM and which country will have the largest Lamellar Ichthyosis market size during the study period (2017–2030)?

• At what CAGR, the Lamellar Ichthyosis market is expected to grow in the 7MM during the study period (2017–2030)?

• What would be the Lamellar Ichthyosis market outlook across the 7MM during the study period (2017–2030)?

• What would be the Lamellar Ichthyosis market growth till 2030 and what will be the resultant market Size in the year 2030?

• How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?

• Lamellar Ichthyosis patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?

• How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies on the basis of their clinical trial results?

• Among the emerging therapies, what are the potential therapies which are expected to disrupt the Lamellar Ichthyosis market? And how the development of gene therapy will impact the therapeutic market of Lamellar Ichthyosis?


Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Lamellar Ichthyosis?

• What is the historical Lamellar Ichthyosis patient pool in the 7MM covering the United States, EU5 (Germany, Spain, France, Italy, the United Kingdom) and Japan?

• What would be the forecasted patient pool of Lamellar Ichthyosis in the 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Lamellar Ichthyosis?

• Out of all the 7MM countries, which country would have the highest prevalent population of Lamellar Ichthyosis during the study period (2017–2030)?

• At what CAGR the population is expected to grow in the 7MM during the study period (2017–2030)?

• What are the various recent and upcoming events which are expected to improve the diagnosis of Lamellar Ichthyosis?

• What are the different types of genetic mutations in Lamellar Ichthyosis? And among them, which are more prominent in Lamellar Ichthyosis patients?

• What proportion of Lamellar Ichthyosis patients are suffering from moderate to severe symptoms?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the treatment of Lamellar Ichthyosis along with the approved therapy?

• What are the current treatment guidelines for the treatment of Lamellar Ichthyosis in US, Europe and Japan?

• What are the Lamellar Ichthyosis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?

• How many companies are developing therapies for the treatment of Lamellar Ichthyosis?

• How many therapies are developed by each company for the treatment of Lamellar Ichthyosis?

• How many emerging therapies are in mid stage, and late stage of development for the treatment of Lamellar Ichthyosis?

• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lamellar Ichthyosis therapies?

• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?

• What are the clinical studies going on for Lamellar Ichthyosis and their status?

• What are the key designations that have been granted for the emerging therapies for Lamellar Ichthyosis?

• What are the global historical and forecasted market of Lamellar Ichthyosis?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Lamellar Ichthyosis market
  • To understand the future market competition in the Lamellar Ichthyosis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Lamellar Ichthyosis in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Lamellar Ichthyosis market
  • To understand the future market competition in the Lamellar Ichthyosis market.


What is Lamellar Ichthyosis?

Lamellar Ichthyosis is a type of autosomal recessive congenital Ichthyosis (ARCI), which is clinically and genetically heterogeneous group of dermatological scaly skin disorders.


What are the Lamellar Ichthyosis pipeline products?

Lamellar Ichthyosis pipeline comprise of CD5789 Cream (Mayne Pharma), KB105(Krystal Biotech), TMB-001(Timber Pharmaceuticals) and others that shall fuel the growth of the market during the forecast period, i.e., 2019–2030.


Which are the leading companies in Lamellar Ichthyosis market?

Key players at the global level are Mayne Pharma, Krystal Biotech, Timber Pharmaceuticals and others working in Lamellar Ichthyosis market.


Which therapy is expected to grab the maximum share in Lamellar Ichthyosis market during the study period 2017-30?

Of the emerging therapies, KB105 - a gene therapy can be a promising treatment and grab the maximum Lamellar Ichthyosis market share.


How is epidemiology segmented for Lamellar Ichthyosis?

Lamellar Ichthyosis Epidemiology is segmented into Age-standardized cases and Diagnosed and Treatable Cases of Lamellar Ichthyosis for the study period 2017–2030.

1. Key Insights

2. Executive Summary of Lamellar Ichthyosis

3. SWOT Analysis for Lamellar Ichthyosis

4. Lamellar Ichthyosis: Patient Share Overview at a Glance

4.1. Total Patient Share (%) Distribution of Lamellar Ichthyosis in 2017 (United States)

4.2. Total Patient Share (%) Distribution of Lamellar Ichthyosis in 2030 (United States)

5. Lamellar Ichthyosis: Market Overview at a Glance

5.1. Total Market Share (%) Distribution of Lamellar Ichthyosis in 2017

5.2. Total Market Share (%) Distribution of Lamellar Ichthyosis in 2030

6. Lamellar Ichthyosis (LI): Disease Background and Overview

6.1. Introduction

6.1.1. Ichthyosis

6.1.2. Lamellar Ichthyosis

6.2. Signs and Symptoms of Lamellar Ichthyosis

6.3. Pathogenesis of Lamellar Ichthyosis

6.4. Etiology

6.5. Diagnosis of Lamellar Ichthyosis

6.5.1. Scoring System for Diagnosis

6.6. Algorithm for the Diagnosis of Congenital Ichthyosis Types

7. Epidemiology and Patient Population

7.1. Key Findings: 7MM

7.2. Assumptions and Rationale: 7MM

7.3. Total Prevalent Cases of Lamellar Ichthyosis in the 7MM

7.4. Total Diagnosed Cases of Lamellar Ichthyosis in the 7MM

7.5. Genetic Mutation-specific Cases of Lamellar Ichthyosis in the 7MM

7.6. Severity-Specific Cases of Lamellar Ichthyosis in the 7MM

7.7. Total Treated Cases of Lamellar Ichthyosis in the 7MM

8. United States

8.1. Total Prevalent Cases of Lamellar Ichthyosis in the United States

8.2. Total Diagnosed Cases of Lamellar Ichthyosis in the United States

8.3. Genetic Mutation-specific Cases of LI in the United States

8.4. Severity-Specific Cases of Lamellar Ichthyosis in the United States

8.5. Total Treated Cases of Lamellar Ichthyosis in the United States

9. EU-5 Country-wise Epidemiology

9.1. Germany

9.1.1. Total Prevalent cases of Lamellar Ichthyosis in Germany

9.1.2. Total Diagnosed cases of Lamellar Ichthyosis in Germany

9.1.3. Genetic mutation-specific cases of Lamellar Ichthyosis in Germany

9.1.4. Severity-Specific cases of Lamellar Ichthyosis in Germany

9.1.5. Total Treated cases of Lamellar Ichthyosis in Germany

9.2. France

9.2.1. Total Prevalent cases of Lamellar Ichthyosis in France

9.2.2. Total Diagnosed cases of Lamellar Ichthyosis in France

9.2.3. Genetic mutation-specific cases of Lamellar Ichthyosis in France

9.2.4. Severity-Specific Cases of Lamellar Ichthyosis in France

9.2.5. Total Treated Case of Lamellar Ichthyosis in France

9.3. Italy

9.3.1. Total Prevalent cases of Lamellar Ichthyosis in Italy

9.3.2. Total Diagnosed cases of Lamellar Ichthyosis in Italy

9.3.3. Genetic mutation-specific cases of Lamellar Ichthyosis in Italy

9.3.4. Severity-Specific Cases of Lamellar Ichthyosis in Italy

9.3.5. Total Treated Case of Lamellar Ichthyosis in Italy

9.4. Spain

9.4.1. Total Prevalent cases of Lamellar Ichthyosis in Spain

9.4.2. Total Diagnosed cases of Lamellar Ichthyosis in Spain

9.4.3. Genetic mutation-specific cases of Lamellar Ichthyosis in Spain

9.4.4. Severity-Specific Cases of Lamellar Ichthyosis in Spain

9.4.5. Total Treated Case of Lamellar Ichthyosis in Spain

9.5. United Kingdom

9.5.1. Total Prevalent cases of Lamellar Ichthyosis in the United Kingdom

9.5.2. Total Diagnosed cases of Lamellar Ichthyosis in the United Kingdom

9.5.3. Genetic mutation-specific cases of Lamellar Ichthyosis in the United Kingdom

9.5.4. Severity-Specific Cases of Lamellar Ichthyosis in the United Kingdom

9.5.5. Total Treated Case of Lamellar Ichthyosis in the United Kingdom

10. Japan

10.1. Total Prevalent Cases of Lamellar Ichthyosis in Japan

10.2. Total Diagnosed Cases of Lamellar Ichthyosis in Japan

10.3. Genetic Mutation-specific Cases of Lamellar Ichthyosis in Japan

10.4. Severity-specific Cases of Lamellar Ichthyosis in Japan

10.5. Total Treated Cases of Lamellar Ichthyosis in Japan

11. Current Management Practices of Lamellar Ichthyosis

11.1. Guidelines for Congenital Ichthyosis

12. Patient Journey of Lamellar Ichthyosis

13. Unmet Needs

14. Key Endpoints Targeting by Emerging Therapies in Lamellar Ichthyosis Trials

15. Emerging Therapies

15.1.Key Cross

15.2.TMB-001 (Isotretinoin, formerly known as PAT-001): Timber Pharmaceuticals

15.2.1. Product Description

15.2.2. Other Developmental Activities

15.2.3. Clinical Development

15.2.4. Safety and Efficacy

15.3.Trifarotene (CD5789): Galderma/Mayne Pharma

15.3.1. Product Description

15.3.2. Other Developmental Activities

15.3.3. Clinical Development

15.4. KB105: Krystal Biotech

15.4.1. Product Description

15.4.2. Other Developmental Activities

15.4.3. Clinical Developmental

15.4.4. Safety and Efficacy

16. Conjoint Analysis of Lamellar Ichthyosis Therapies

17. Lamellar Ichthyosis: Seven Major Market Analysis

17.1. Key Findings

17.2. Market Outlook: 7MM

17.3. Total Market Size of Lamellar Ichthyosis in the 7MM

17.4. Market Size by Therapies of Lamellar Ichthyosis in the 7MM

18. United States Market Size

18.1. Total Market size of Lamellar Ichthyosis in the United States

18.2. Market size by Therapies of Lamellar Ichthyosis in the United States

19. EU-5 Market Size

19.1.Germany Market Size

19.1.1. Total Market size of Lamellar Ichthyosis in Germany

19.1.2. Market size by Therapies of Lamellar Ichthyosis in Germany

19.2.France Market Size

19.2.1. Total Market size of Lamellar Ichthyosis in France

19.2.2. Market size by therapies of Lamellar Ichthyosis in France

19.3.Italy Market Size

19.3.1. Total Market size of Lamellar Ichthyosis in Italy

19.3.2. Market size by Therapies of Lamellar Ichthyosis in Italy

19.4.Spain Market Size

19.4.1. Total Market size of Lamellar Ichthyosis In Spain

19.4.2. Market size by Therapies of Lamellar Ichthyosis In Spain

19.5.United Kingdom Market Size

19.5.1. Total Market size of Lamellar Ichthyosis in the United Kingdom

19.5.2. Market size by Therapies of Lamellar Ichthyosis in the United Kingdom

20. Japan Market Size

20.1. Total Market size of Lamellar Ichthyosis in Japan

20.2. Market size By Therapies of Lamellar Ichthyosis in Japan

21. Market Access and Reimbursement Scenario of Lamellar Ichthyosis Therapies

22. Market Drivers

23. Market Barriers

24. Appendix

24.1. Bibliography

24.2. Report Methodology

25. Disclaimer

26. DelveInsight Capabilities

27. About DelveInsight

List Of Tables:

Table 1 Summary of Lamellar Ichthyosis Market, Epidemiology, and Key Events (2017-2030)

Table 2 Symptoms of Lamellar Ichthyosis

Table 3 Molecular Genetics of Autosomal Recessive Congenital Ichthyosis: Most Common Genetic Causes

Table 4 Molecular Genetics of Autosomal Recessive Congenital Ichthyosis: Less Common Genetic Causes

Table 5 Lamellar Scale Severity Standards-arm

Table 6 Investigator's Global Assessment (IGA) Scale

Table 7 Major Sources Used

Table 8 Total Prevalent Cases of LI in the 7MM (2017-2030)

Table 9 Total Diagnosed Cases of LI in the 7MM (2017-2030)

Table 10 Genetic Mutation-specific Cases of LI in the 7MM (2017-2030)

Table 11 Severity-specific Cases of LI in the 7MM (2017-2030)

Table 12 Total Treated Cases of LI in the 7MM (2017-2030)

Table 13 Total Prevalent Cases of LI in the United States (2017-2030)

Table 14 Total Diagnosed Cases of LI in the United States (2017-2030)

Table 15 Genetic Mutation-specific Cases of LI in the United States (2017-2030)

Table 16 Severity-specific Cases of LI in the United States (2017-2030)

Table 17 Total Treated Cases of LI in the United States (2017-2030)

Table 18 Total Prevalent Cases of LI in Germany (2017-2030)

Table 19 Total Diagnosed Cases of LI in Germany (2017-2030)

Table 20 Genetic Mutation-specific Cases of LI in Germany (2017-2030)

Table 21 Severity-specific Cases of LI in Germany (2017-2030)

Table 22 Total Treated Cases of LI in Germany (2017-2030)

Table 23 Total Prevalent Cases of LI in France (2017-2030)

Table 24 Total Diagnosed Cases of LI in France (2017-2030)

Table 25 Genetic Mutation-specific Cases of LI in France (2017-2030)

Table 26 Severity-specific Cases of LI in France (2017-2030)

Table 27 Total Treated Case of LI in France (2017-2030)

Table 28 Total Prevalent Cases of LI in Italy (2017-2030)

Table 29 Total Diagnosed Cases of LI in Italy (2017-2030)

Table 30 Genetic Mutation-specific Cases of LI in Italy (2017-2030)

Table 31 Severity-specific Cases of LI in Italy (2017-2030)

Table 32 Total Treated Case of LI in Italy (2017-2030)

Table 33 Total Prevalent Cases of LI in Spain (2017-2030)

Table 34 Total Diagnosed Cases of LI in Spain (2017-2030)

Table 35 Genetic Mutation-specific Cases of LI in Spain (2017-2030)

Table 36 Severity-specific Cases of LI in Spain (2017-2030)

Table 37 Total Treated Case of LI in Spain (2017-2030)

Table 38 Total Prevalent Cases of LI In the United Kingdom (2017-2030)

Table 39 Total Diagnosed Cases of LI In the United Kingdom (2017-2030)

Table 40 Genetic Mutation-specific Cases of LI in the United Kingdom (2017-2030)

Table 41 Severity-specific Cases of LI in the United Kingdom (2017-2030)

Table 42 Total Treated Case of LI in the United Kingdom (2017-2030)

Table 43 Total Prevalent Cases of LI in Japan (2017-2030)

Table 44 Total Diagnosed Cases of LI Japan (2017-2030)

Table 45 Genetic Mutation-specific Cases of LI in Japan (2017-2030)

Table 46 Severity-specific Cases of LI in Japan (2017-2030)

Table 47 Total Treated Cases of LI in Japan (2017-2030)

Table 48 Overview of Important Topical Agents For Ichthyosis

Table 49 Grades of Recommendation By The Scottish Intercollegiate Guidelines Network (Sign)

Table 50 Management of Complications of Congenital Ichthyosis: Recommendations With Level of Evidence and Grade

Table 51 Management of The Particularities of Congenital Ichthyosis Either Related to the Age of the Patient or the Form of Ichthyosis: Recommendations with Level of Evidence And Grade

Table 52 Emerging Drugs Key-cross Competition

Table 53 TMB-001, Clinical Trial Description, 2020

Table 54 Trifarotene (CD5789 Cream), Clinical Trial Description, 2020

Table 55 KB105, Clinical Trial Description, 2020

Table 56 7MM Market Size of Lamellar Ichthyosis, in USD Million (2017-2030)

Table 57 Market Size by Therapies of Lamellar Ichthyosis in the 7MM, in USD Million (2017-2030)

Table 58 Total Market Size of Lamellar Ichthyosis in the United States, In USD Millions (2017-2030)

Table 59 Market Size by Therapies of Lamellar Ichthyosis in the United States, in USD Millions (2017-2030)

Table 60 Total Market Size of Lamellar Ichthyosis in Germany, in USD Millions (2017-2030)

Table 61 Market Size by Therapies of Lamellar Ichthyosis in Germany, in USD Millions (2017-2030)

Table 62 Total Market Size of Lamellar Ichthyosis in France, in USD Millions (2017-2030)

Table 63 Market Size by Therapies of Lamellar Ichthyosis in France, in USD Millions (2017-2030)

Table 64 Total Market Size of Lamellar Ichthyosis in Italy, In USD Millions (2017-2030)

Table 65 Market Size by Therapies of Lamellar Ichthyosis in Italy, in USD Millions (2017-2030)

Table 66 Total Market Size of Lamellar Ichthyosis in Spain, in USD Millions (2017-2030)

Table 67 Market Size by Therapies of Lamellar Ichthyosis in Spain, in USD Millions (2017-2030)

Table 68 Total Market Size of Lamellar Ichthyosis in the United Kingdom, in USD Millions (2017-2030)

Table 69 Market Size by Therapies of Lamellar Ichthyosis in the United Kingdom, in USD Millions (2017-2030)

Table 70 Total Market Size of Lamellar Ichthyosis In Japan, in USD Millions (2017-2030)

Table 71 Market Size by Therapies of Lamellar Ichthyosis in Japan, In USD Millions (2017-2030)


List Of Figures:

Figure 1 Lamellar Ichthyosis SWOT Analysis

Figure 2 Major Function of Skin

Figure 3 Cross-section of Skin

Figure 4 Structure of the Cell Membrane Zone of Cornified Cells and Key Molecules for The Pathogenesis Of Congenital Ichthyoses

Figure 5 Autosomal Recessive Pattern of The Disease

Figure 6 Overview of the Diagnostic Procedures for Patients With Suspected Ichthyosis

Figure 7 Total Prevalent Cases of LI in The 7MM (2017-2030)

Figure 8 Total Diagnosed Cases of LI In The 7MM (2017-2030)

Figure 9 Genetic Mutation-specific Cases of LI in The 7MM (2017-2030)

Figure 10 Severity-specific Cases of LI in the 7MM (2017-2030)

Figure 11 Total Treated Cases of Li in the 7MM (2017-2030)

Figure 12 Total Prevalent Cases of LI in the United States (2017-2030)

Figure 13 Total Diagnosed Cases of LI in the United States (2017-2030)

Figure 14 Genetic Mutation-specific Cases Of LI in the United States (2017-2030)

Figure 15 Severity-specific Cases of LI in the United States (2017-2030)

Figure 16 Total Treated Cases of LI in the United States (2017-2030)

Figure 17 Total Prevalent Cases of LI in Germany (2017-2030)

Figure 18 Total Diagnosed Cases of LI in Germany (2017-2030)

Figure 19 Genetic Mutation-specific Cases of LI in Germany (2017-2030)

Figure 20 Severity-specific Cases of LI in Germany (2017-2030)

Figure 21 Total Treated Cases of LI in Germany (2017-2030)

Figure 22 Total Prevalent Cases of LI in France (2017-2030)

Figure 23 Total Diagnosed Cases of LI in France (2017-2030)

Figure 24 Genetic Mutation-specific Cases of LI in France (2017-2030)

Figure 25 Severity-specific Cases of LI in France (2017-2030)

Figure 26 Total Treated Case of LI in France (2017-2030)

Figure 27 Total Prevalent Cases of LI in Italy (2017-2030)

Figure 28 Total Diagnosed Cases of LI in Italy (2017-2030)

Figure 29 Genetic Mutation-specific Cases of LI in Italy (2017-2030)

Figure 30 Severity-specific Cases of LI in Italy (2017-2030)

Figure 31 Total Treated Case of LI in Italy (2017-2030)

Figure 32 Total Prevalent Cases of LI in Spain (2017-2030)

Figure 33 Total Diagnosed Cases of LI in Spain (2017-2030)

Figure 34 Genetic Mutation-specific Cases of LI in Spain (2017-2030)

Figure 35 Severity-specific Cases of LI in Spain (2017-2030)

Figure 36 Total Treated Case of LI in Spain (2017-2030)

Figure 37 Total Prevalent Cases of LI in the United Kingdom (2017-2030)

Figure 38 Total Diagnosed Cases of LI in the United Kingdom (2017-2030)

Figure 39 Genetic Mutation-specific Cases of LI in the United Kingdom (2017-2030)

Figure 40 Severity-specific Cases of LI in the United Kingdom (2017-2030)

Figure 41 Total Treated Case of LI in the United Kingdom (2017-2030)

Figure 42 Total Prevalent Cases of LI in Japan (2017-2030)

Figure 43 Total Diagnosed Cases of LI in Japan (2017-2030)

Figure 44 Genetic Mutation-specific Cases of LI in Japan (2017-2030)

Figure 45 Severity-specific Cases of LI in Japan (2017-2030)

Figure 46 Total Treated Cases of LI in Japan (2017-2030)

Figure 47 Requirements for Ideal Treatment of Ichthyosis

Figure 48 Overview of Therapeutic Management of Ichthyosis

Figure 49 Unmet Needs of Lamellar Ichthyosis

Figure 50 Total Market Size of Lamellar Ichthyosis in the 7MM, in USD Million (2017-2030)

Figure 51 Market Size by Therapies of Lamellar Ichthyosis in the 7MM, in USD Million (2017-2030)

Figure 52 Total Market Size of Lamellar Ichthyosis In The United States, in USD Millions (2017-2030)

Figure 53 Market Size by Therapies of Lamellar Ichthyosis in the United States, in USD Millions (2017-2030)

Figure 54 Total Market Size of Lamellar Ichthyosis in Germany, in USD Millions (2017-2030)

Figure 55 Market Size by Therapies of Lamellar Ichthyosis in Germany, in USD Millions (2017-2030)

Figure 56 Total Market Size of Lamellar Ichthyosis in France, in USD Millions (2017-2030)

Figure 57 Market Size by Therapies of Lamellar Ichthyosis in France, in USD Millions (2017-2030)

Figure 58 Total Market Size of Lamellar Ichthyosis in Italy, in USD Millions (2017-2030)

Figure 59 Market Size by Therapies of Lamellar Ichthyosis in Italy, in USD Millions (2017-2030)

Figure 60 Total Market Size of Lamellar Ichthyosis in Spain, in USD Millions (2017-2030)

Figure 61 Market Size by Therapies of Lamellar Ichthyosis in Spain, in USD Millions (2017-2030)

Figure 62 Total Market Size of Lamellar Ichthyosis in the United Kingdom, in USD Millions (2017-2030)

Figure 63 Market Size by Therapies of Lamellar Ichthyosis in the United Kingdom, in USD Millions (2017-2030)

Figure 64 Market Size of Lamellar Ichthyosis in Japan, in USD Millions (2017-2030)

Figure 65 Market Size by Therapies of Lamellar Ichthyosis in Japan, in USD Millions (2017-2030)

Figure 66 Market Drivers of Lamellar Ichthyosis

Figure 67 Market Barriers of Lamellar Ichthyosis

  • Tags:
  • Lamellar Ichthyosis (LI)-Market Ins...
  • Epidemiology and Market Forecast-2...

Forward to Friend

Need A Quote